We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Takeda to Buy Brazilian Pharmaceutical Company Multilab

By HospiMedica International staff writers
Posted on 05 Jun 2012
Takeda Pharmaceutical (Osaka, Japan), Asia’s largest drugmaker, has agreed to buy Multilab Industria e Comercio de Productos Farmaceuticos (Multilab; Sao Jeronimo, Brazil), in a move intended to enhance its business infrastructure in Brazil.

The acquisition of Multilab for USD 246 million will position Takeda as one of the top ten pharmaceutical companies in Brazil. Multilab has well established distribution through regional wholesalers and small to mid-sized independent pharmacies, in particular in emerging regions of the country, which is expected to complement Takeda’s strong relationships with major wholesalers, retail chains, and pharmacies in more established cities and state capitals. The transaction is expected to be completed by the end of September 2012.

Takeda already has an established presence in Brazil, manufacturing and marketing both prescription drugs as well as well-known brands such as the analgesic Neosaldina, the digestive Eparema, and Nebacetin, an antibacterial product. Multilab’s leading products include Multigrip, the country’s best selling over the counter (OTC) product for cold and flu treatment, which Takeda believes will be an excellent addition to its existing OTC product line in Brazil.

“This acquisition significantly reinforces Takeda’s position in Brazil, which is the world’s sixth largest economy and the biggest in South America,” said Jostein Davidsen, head of emerging markets commercial operations for Takeda. “Takeda has ambitious plans for growth in emerging markets. Brazil is our second largest emerging market after Russia/CIS in terms of revenues, and the acquisition of Multilab is a clear signal of our intention to become a significant player both in Brazil and other high-growth markets.”

“Multilab will benefit from becoming part of the Takeda group, enabling the company to reinforce its market position and reach more patients with its key products in Brazil,” said Hilton Cavedon, executive director of Multilab.

Related Links:

Takeda Pharmaceutical
Multilab Industria e Comercio de Productos Farmaceuticos



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Monitor Cart
Tryten S5
New
Mobile Barrier
Tilted Mobile Leaded Barrier

Latest Business News

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024

Boston Scientific to Acquire AFib Ablation Company Cortex